Wang 2008c.
Methods | Allocation: randomised. Blindness: not stated. Duration: 8 weeks, 2003‐2007 (one‐week wash‐out) Setting: Baoji rehabilitation hospital, Shanxi, China. |
|
Participants | Diagnosis: schizophrenia CCMD‐3. N = 64. Age: Quetiapine: 66.08 ± 4.22 years; perphenazine: 65.73 ± 5.53 years. Sex: F27, M37 (Quetiapine (n = 32): M17 F15; perphenazine (n = 32): M20 F12). History: length of illness Quetiapine: 3.6 ± 0.5months; perphenazine: 3.4 ± 0.6months. Included: Schizophrenia CCMD‐3; age ≥ 60 years, first episode; BPRS ≥ 35. Exclusion: drug abuse; organic dysphrenia. Consent: not stated.. |
|
Interventions | 1. Perphenazine: start from 4 mg/day to treatment dosage: 20‐40 mg/day, average:24.5 ± 5.3mg/day, n = 32. 2. Quetiapine: start from 50 mg/day to the treatment dosage: 200‐400 mg/day, average dosage: 258.92 ± 28.13mg/day, n = 32. |
|
Outcomes | Lab data: blood test, urine test, liver function, kidney function, ECG, blood pressure. Adverse events. BPRS score. TESS score. Clinical prognosis assessment: decreased rate of BPRS score ≥ 75%‐‐recovery; 50% to 74% markedly improved; 25% to 49% improved; < 25% no effect. |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Randomised – no further details. |
Allocation concealment (selection bias) | Unclear risk | Not described. |
Blinding (performance bias and detection bias) All outcomes | Unclear risk | Not described. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | In the quetiapine group, n = 1 left the study due to drowsiness. In the perphenazine group n = 3 left due to EPS. Missing data from participants leaving the study early were not included in analyses. |
Selective reporting (reporting bias) | Unclear risk | None detected. |
Other bias | Unclear risk | Funding: not stated. Rating scales: raters not stated to be independent of treatment. |